1
|
de Campos Vieira Abib S, Chui CH, Cox S, Abdelhafeez AH, Fernandez-Pineda I, Elgendy A, Karpelowsky J, Lobos P, Wijnen M, Fuchs J, Hayes A, Gerstle JT. International Society of Paediatric Surgical Oncology (IPSO) Surgical Practice Guidelines. Ecancermedicalscience 2022; 16:1356. [PMID: 35510137 PMCID: PMC9023308 DOI: 10.3332/ecancer.2022.1356] [Citation(s) in RCA: 9] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/26/2021] [Indexed: 12/14/2022] Open
Abstract
Most children with tumors will require one or more surgical interventions as part of the care and treatment, including making a diagnosis, obtaining adequate venous access, performing a surgical resection for solid tumors (with staging and reconstruction), performing procedures for cancer prevention and its late effects, and managing complications of treatment; all with the goal of improving survival and quality of life. It is important for surgeons to adhere to sound pediatric surgical oncology principles, as they are closely associated with improved local control and survival. Unfortunately, there is a significant disparity in survival rates in low and middle income countries, when compared to those from high income countries. The International Society of Paediatric Surgical Oncology (IPSO) is the leading organization that deals with pediatric surgical oncology worldwide. This organization allows experts in the field from around the globe to gather and address the surgical needs of children with cancer. IPSO has been invited to contribute surgical guidance as part of the World Health Organization Initiative for Childhood Cancer. One of our goals is to provide surgical guidance for different scenarios, including those experienced in High- (HICs) and Low- and Middle-Income Countries (LMICs). With this in mind, the following guidelines have been developed by authors from both HICs and LMICs. These have been further validated by experts with the aim of providing evidence-based information for surgeons who care for children with cancer. We hope that this initiative will benefit children worldwide in the best way possible. Simone Abib, IPSO President Justin T Gerstle, IPSO Education Committee Chair Chan Hon Chui, IPSO Secretary.
Collapse
Affiliation(s)
- Simone de Campos Vieira Abib
- Pediatric Oncology Institute, GRAACC, Federal University of São Paulo, Rua Pedro de Toledo, 572 - Vila Clementino, São Paulo, SP 04021-001, Brazil
| | - Chan Hon Chui
- Surgery Centre for Children, Mount Elizabeth Medical Centre, 3 Mount Elizabeth, 228510, Singapore
| | - Sharon Cox
- Division of Paediatric Surgery, Red Cross War Memorial Children’s Hospital, University of Cape Town, Cape Town, South Africa
| | - Abdelhafeez H Abdelhafeez
- Department of Surgery, St Jude Research Hospital 262 Danny Thomas Place. MS133, Memphis, TN 38105, USA
| | - Israel Fernandez-Pineda
- Department of Pediatric Surgery, Virgen del Rocio Children’s Hospital, Av Manuel Siurot S/NN, Sevilla 41013, Spain
| | - Ahmed Elgendy
- Surgical Oncology Unit, Faculty of Medicine, Tanta University, Elgiesh Street, 31111, Tanta, Gharbeya, Egypt
| | - Jonathan Karpelowsky
- Department of Paediatric Surgery, Children’s Hospital at Westmead, Westmead NSW 2145, Australia
| | - Pablo Lobos
- Pediatric Surgery Division, Hospital Italiano de Buenos Aires, Andrés Lamas 812, Buenos Aires 1406, Argentina
| | - Marc Wijnen
- Department of Surgery, Princess Maxima Center for Pediatric Oncology, Huispostnummer KE 01.129.2, Postbus 85090, Utretcht 3508AB, The Netherlands
| | - Jörg Fuchs
- Department of Pediatric Surgery and Pediatric Urology, University of Tuebingen, Hoppe-Seyler-Str. 3, Tübingen 72076, Germany
| | - Andrea Hayes
- Department of Surgery, Howard University Hospital, 1851 9th Street NW, 4th Floor, Washington, DC 20059, USA
| | - Justin T Gerstle
- Department of Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
| |
Collapse
|
4
|
Bus A, van Hoeck V, Langbeen A, Leroy JLMR, Bols PEJ. Effects of vitrification on the viability of alginate encapsulated isolated bovine pre-antral follicles. J Assist Reprod Genet 2018; 35:1187-1199. [PMID: 29797286 DOI: 10.1007/s10815-018-1208-3] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/12/2018] [Accepted: 05/09/2018] [Indexed: 02/07/2023] Open
Abstract
PURPOSE Individual follicle cryopreservation techniques, without hydrogel support, are labor-intensive and a substantial proportion of isolated follicles are lost during handling and after warming. Therefore, the viability and morphology of isolated bovine (as a model for human) pre-antral follicles after vitrification and warming, when encapsulated in alginate beads, were investigated. METHODS Bovine pre-antral follicles were mechanically isolated and divided into four different groups: (1) culture in 2% alginate beads (3D system) and vitrification in beads using mesh cups (3DVIT), (2) culture in 2% alginate beads (3DCUL), (3) culture in 96-well plates (2D system) and vitrification using High Security Vitrification straws® (2DVIT), (4) culture in a 2D system (2DCUL). The same vitrification and warming protocols were used for embedded (3DVIT) and non-embedded follicles (2DVIT). RESULTS No differences were observed in follicle viability between group 2DCUL and 3DCUL. Group 3DVIT showed the lowest viability (45.9%) according to calcein and neutral red staining among all groups. Group 2DVIT displayed the highest viability (87.5%) and largest percentage of follicles with a well-preserved morphology. CONCLUSIONS Our results show that, using a vitification protocol optimized for non-embedded follicles, 2D culture is more effective in vitrifying isolated follicles. However, embedding in alginate allow to handle follicles more efficiently, i.e., without excessive manipulation and thus less labor-intensive in combination with a reduced loss of follicles during the procedure. Based on the increased work efficiency, but lower viability and higher proportion of follicles showing impaired morphology, we consider it advantageous to optimize the protocol for the vitrification of embedded follicles to increase survival and maintain morphology after vitrification.
Collapse
Affiliation(s)
- Anniek Bus
- Faculty of Pharmaceutical, Biomedical and Veterinary Sciences, Laboratory of Veterinary Physiology and Biochemistry, Gamete Research Centre, University of Antwerp, Universiteitsplein 1, Gebouw U, 2610, Wilrijk, Belgium.
| | - Veerle van Hoeck
- Faculty of Pharmaceutical, Biomedical and Veterinary Sciences, Laboratory of Veterinary Physiology and Biochemistry, Gamete Research Centre, University of Antwerp, Universiteitsplein 1, Gebouw U, 2610, Wilrijk, Belgium
| | - An Langbeen
- Faculty of Pharmaceutical, Biomedical and Veterinary Sciences, Laboratory of Veterinary Physiology and Biochemistry, Gamete Research Centre, University of Antwerp, Universiteitsplein 1, Gebouw U, 2610, Wilrijk, Belgium
| | - Jo L M R Leroy
- Faculty of Pharmaceutical, Biomedical and Veterinary Sciences, Laboratory of Veterinary Physiology and Biochemistry, Gamete Research Centre, University of Antwerp, Universiteitsplein 1, Gebouw U, 2610, Wilrijk, Belgium
| | - Peter E J Bols
- Faculty of Pharmaceutical, Biomedical and Veterinary Sciences, Laboratory of Veterinary Physiology and Biochemistry, Gamete Research Centre, University of Antwerp, Universiteitsplein 1, Gebouw U, 2610, Wilrijk, Belgium
| |
Collapse
|
11
|
Loren AW, Mangu PB, Beck LN, Brennan L, Magdalinski AJ, Partridge AH, Quinn G, Wallace WH, Oktay K. Fertility preservation for patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 2013; 31:2500-10. [PMID: 23715580 PMCID: PMC5321083 DOI: 10.1200/jco.2013.49.2678] [Citation(s) in RCA: 1077] [Impact Index Per Article: 97.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022] Open
Abstract
PURPOSE To update guidance for health care providers about fertility preservation for adults and children with cancer. METHODS A systematic review of the literature published from March 2006 through January 2013 was completed using MEDLINE and the Cochrane Collaboration Library. An Update Panel reviewed the evidence and updated the recommendation language. RESULTS There were 222 new publications that met inclusion criteria. A majority were observational studies, cohort studies, and case series or reports, with few randomized clinical trials. After review of the new evidence, the Update Panel concluded that no major, substantive revisions to the 2006 American Society of Clinical Oncology recommendations were warranted, but clarifications were added. RECOMMENDATIONS As part of education and informed consent before cancer therapy, health care providers (including medical oncologists, radiation oncologists, gynecologic oncologists, urologists, hematologists, pediatric oncologists, and surgeons) should address the possibility of infertility with patients treated during their reproductive years (or with parents or guardians of children) and be prepared to discuss fertility preservation options and/or to refer all potential patients to appropriate reproductive specialists. Although patients may be focused initially on their cancer diagnosis, the Update Panel encourages providers to advise patients regarding potential threats to fertility as early as possible in the treatment process so as to allow for the widest array of options for fertility preservation. The discussion should be documented. Sperm and embryo cryopreservation as well as oocyte cryopreservation are considered standard practice and are widely available. Other fertility preservation methods should be considered investigational and should be performed by providers with the necessary expertise.
Collapse
Affiliation(s)
- Alison W. Loren
- Alison W. Loren, Perelman School of Medicine at the University of Pennsylvania, Philadelphia; Anthony J. Magdalinski, Private Practice, Sellersville, PA; Pamela B. Mangu, American Society of Clinical Oncology, Alexandria, VA; Lindsay Nohr Beck, LIVESTRONG Foundation's Fertile Hope Program, Austin, TX; Kutluk Oktay, Innovation Institute for Fertility Preservation, New York Medical College, Rye and New York, NY; Lawrence Brennan, Oncology Hematology Care, Crestview Hills, KY; Ann H. Partridge, Dana-Farber Cancer Institute, Boston, MA; Gwendolyn Quinn, Moffitt Cancer Center, Tampa, FL; and W. Hamish Wallace, Royal Hospital for Sick Children, Edinburgh, United Kingdom
| | - Pamela B. Mangu
- Alison W. Loren, Perelman School of Medicine at the University of Pennsylvania, Philadelphia; Anthony J. Magdalinski, Private Practice, Sellersville, PA; Pamela B. Mangu, American Society of Clinical Oncology, Alexandria, VA; Lindsay Nohr Beck, LIVESTRONG Foundation's Fertile Hope Program, Austin, TX; Kutluk Oktay, Innovation Institute for Fertility Preservation, New York Medical College, Rye and New York, NY; Lawrence Brennan, Oncology Hematology Care, Crestview Hills, KY; Ann H. Partridge, Dana-Farber Cancer Institute, Boston, MA; Gwendolyn Quinn, Moffitt Cancer Center, Tampa, FL; and W. Hamish Wallace, Royal Hospital for Sick Children, Edinburgh, United Kingdom
| | - Lindsay Nohr Beck
- Alison W. Loren, Perelman School of Medicine at the University of Pennsylvania, Philadelphia; Anthony J. Magdalinski, Private Practice, Sellersville, PA; Pamela B. Mangu, American Society of Clinical Oncology, Alexandria, VA; Lindsay Nohr Beck, LIVESTRONG Foundation's Fertile Hope Program, Austin, TX; Kutluk Oktay, Innovation Institute for Fertility Preservation, New York Medical College, Rye and New York, NY; Lawrence Brennan, Oncology Hematology Care, Crestview Hills, KY; Ann H. Partridge, Dana-Farber Cancer Institute, Boston, MA; Gwendolyn Quinn, Moffitt Cancer Center, Tampa, FL; and W. Hamish Wallace, Royal Hospital for Sick Children, Edinburgh, United Kingdom
| | - Lawrence Brennan
- Alison W. Loren, Perelman School of Medicine at the University of Pennsylvania, Philadelphia; Anthony J. Magdalinski, Private Practice, Sellersville, PA; Pamela B. Mangu, American Society of Clinical Oncology, Alexandria, VA; Lindsay Nohr Beck, LIVESTRONG Foundation's Fertile Hope Program, Austin, TX; Kutluk Oktay, Innovation Institute for Fertility Preservation, New York Medical College, Rye and New York, NY; Lawrence Brennan, Oncology Hematology Care, Crestview Hills, KY; Ann H. Partridge, Dana-Farber Cancer Institute, Boston, MA; Gwendolyn Quinn, Moffitt Cancer Center, Tampa, FL; and W. Hamish Wallace, Royal Hospital for Sick Children, Edinburgh, United Kingdom
| | - Anthony J. Magdalinski
- Alison W. Loren, Perelman School of Medicine at the University of Pennsylvania, Philadelphia; Anthony J. Magdalinski, Private Practice, Sellersville, PA; Pamela B. Mangu, American Society of Clinical Oncology, Alexandria, VA; Lindsay Nohr Beck, LIVESTRONG Foundation's Fertile Hope Program, Austin, TX; Kutluk Oktay, Innovation Institute for Fertility Preservation, New York Medical College, Rye and New York, NY; Lawrence Brennan, Oncology Hematology Care, Crestview Hills, KY; Ann H. Partridge, Dana-Farber Cancer Institute, Boston, MA; Gwendolyn Quinn, Moffitt Cancer Center, Tampa, FL; and W. Hamish Wallace, Royal Hospital for Sick Children, Edinburgh, United Kingdom
| | - Ann H. Partridge
- Alison W. Loren, Perelman School of Medicine at the University of Pennsylvania, Philadelphia; Anthony J. Magdalinski, Private Practice, Sellersville, PA; Pamela B. Mangu, American Society of Clinical Oncology, Alexandria, VA; Lindsay Nohr Beck, LIVESTRONG Foundation's Fertile Hope Program, Austin, TX; Kutluk Oktay, Innovation Institute for Fertility Preservation, New York Medical College, Rye and New York, NY; Lawrence Brennan, Oncology Hematology Care, Crestview Hills, KY; Ann H. Partridge, Dana-Farber Cancer Institute, Boston, MA; Gwendolyn Quinn, Moffitt Cancer Center, Tampa, FL; and W. Hamish Wallace, Royal Hospital for Sick Children, Edinburgh, United Kingdom
| | - Gwendolyn Quinn
- Alison W. Loren, Perelman School of Medicine at the University of Pennsylvania, Philadelphia; Anthony J. Magdalinski, Private Practice, Sellersville, PA; Pamela B. Mangu, American Society of Clinical Oncology, Alexandria, VA; Lindsay Nohr Beck, LIVESTRONG Foundation's Fertile Hope Program, Austin, TX; Kutluk Oktay, Innovation Institute for Fertility Preservation, New York Medical College, Rye and New York, NY; Lawrence Brennan, Oncology Hematology Care, Crestview Hills, KY; Ann H. Partridge, Dana-Farber Cancer Institute, Boston, MA; Gwendolyn Quinn, Moffitt Cancer Center, Tampa, FL; and W. Hamish Wallace, Royal Hospital for Sick Children, Edinburgh, United Kingdom
| | - W. Hamish Wallace
- Alison W. Loren, Perelman School of Medicine at the University of Pennsylvania, Philadelphia; Anthony J. Magdalinski, Private Practice, Sellersville, PA; Pamela B. Mangu, American Society of Clinical Oncology, Alexandria, VA; Lindsay Nohr Beck, LIVESTRONG Foundation's Fertile Hope Program, Austin, TX; Kutluk Oktay, Innovation Institute for Fertility Preservation, New York Medical College, Rye and New York, NY; Lawrence Brennan, Oncology Hematology Care, Crestview Hills, KY; Ann H. Partridge, Dana-Farber Cancer Institute, Boston, MA; Gwendolyn Quinn, Moffitt Cancer Center, Tampa, FL; and W. Hamish Wallace, Royal Hospital for Sick Children, Edinburgh, United Kingdom
| | - Kutluk Oktay
- Alison W. Loren, Perelman School of Medicine at the University of Pennsylvania, Philadelphia; Anthony J. Magdalinski, Private Practice, Sellersville, PA; Pamela B. Mangu, American Society of Clinical Oncology, Alexandria, VA; Lindsay Nohr Beck, LIVESTRONG Foundation's Fertile Hope Program, Austin, TX; Kutluk Oktay, Innovation Institute for Fertility Preservation, New York Medical College, Rye and New York, NY; Lawrence Brennan, Oncology Hematology Care, Crestview Hills, KY; Ann H. Partridge, Dana-Farber Cancer Institute, Boston, MA; Gwendolyn Quinn, Moffitt Cancer Center, Tampa, FL; and W. Hamish Wallace, Royal Hospital for Sick Children, Edinburgh, United Kingdom
| |
Collapse
|